Osteoarthritis and Bone Disorders News

Patients receiving long-term glucocorticoids should use oral bisphosphonates to reduce the risk for bone loss and fracture, according to new guidelines currently under peer review from the American College of Rheumatology.

Patients with higher BMI prior to total knee arthroplasty typically experience worse overall physical function following surgery, while those with lower osteoarthritis severity experience more positive outcomes, according to data.

The FDA has granted breakthrough device designation to a clinical tool for determining bone fragility and fracture risk for older women, according to an industry press release.

Most older adults with joint pain feel they can manage said pain without physician assistance, while 66% report they treat their joint pain with over-the-counter drugs such as acetaminophen or ibuprofen, according to a poll.

In a large cohort of women, those who were vegetarians demonstrated an elevated risk for hip fracture compared with their meat-eating counterparts, according to recent research.

Addressing the racial disparities that continue to plague health care requires “continuous” work, as well as holding certain providers’ “feet to the fire,” said a presenter at the 2022 Association of Women in Rheumatology annual conference.

A denosumab biosimilar candidate demonstrated noninferior efficacy to its reference product, with similar safety profile, in postmenopausal patients with osteoporosis, according to data published in Arthritis Research & Therapy.

Even modest osteoarthritis pain reductions through intervention would substantially reduce the number of knee replacements, according to data published in Arthritis & Rheumatology.

ORLANDO — Exercise can supplement the efficacy of several therapies used to treat osteoporosis, according to a presenter at the 2022 Rheumatology Nurses Society Annual Conference.

Denosumab is associated with a greater increase in lumbar spine bone mineral density at 12 months compared with ibandronate as a sequential treatment after 12 months of romosozumab therapy, according to study findings published in Bone.